FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

FGEN has been the subject of a number of other research reports. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Stock Performance

FGEN stock opened at $0.48 on Tuesday. The firm has a market cap of $48.37 million, a P/E ratio of -0.39 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.93. The stock has a 50-day simple moving average of $0.36 and a 200-day simple moving average of $0.55.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the company earned ($0.52) earnings per share. On average, equities research analysts predict that FibroGen will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares in the last quarter. FMR LLC increased its stake in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of FibroGen during the third quarter worth $307,000. Point72 DIFC Ltd lifted its position in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.